Michael Forer

Rothschild & Co. Asset Management US, Inc. (R&Co) is an asset management firm headquartered in Stamford, Connecticut. The firm was founded in 1962 and formerly known as Rothschild Asset Management, Inc. They are a wholly-owned subsidiary of Great Lakes Advisors LLC and their ultimate parent is Wintrust Financial Corp. (NASDAQ: WTFC). R&Co provides investment advisory and sub-advisory services on a discretionary basis to a broad range of clients. They also provide non-discretionary investment advice to various wrap model delivery managed account programs.

Norton Rose provides legal services. It provides business law service from a network of offices located across Europe, Asia, and the Middle East. The firm offers business law services in international corporate finance, financial institutions, transport, energy, and technology. The company was founded in 1988 and is headquartered in London, UK.

Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London.

Rose Pharma A/S provides pharmaceutical products for treatment of pain in connection with irritable bowel syndrome. It develops treatments for irritable bowel syndrome (IBS) and functional dyspepsia, and disorders. The firm focuses on the medical applications of gastrointestinal hormones. The company was founded in 2003 and is headquartered in Roskilde, Denmark.

The Law Society of Upper Canada engages in the provision of legal services. The company was founded in 1797 and is headquartered in Toronto, Canada.

Founded in 2007 by Stephen Evans-Freke and Peter Corr, Auven Therapeutics Management LLLP is a global private equity firm located in St. Thomas, Virgin Islands. They also have operations in New York City and Europe. The firm was formerly known as Celtic Therapeutics Management, which was the successor firm to Celtic Pharma Management LP.

Auven Therapeutics Holdings LP invests in late stage companies developing therapeutic products (small-molecules & biologics) and related diagnostics. It provides financing for buyouts and late stage capital requirements. It makes controlling investments.